Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naive With Metastatic Prostate Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 27 Aug 2007
At a glance
- Drugs Bicalutamide; Goserelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 27 Aug 2007 Status changed from recruiting to withdrawn. This study was withdrawn prior to recruitment.
- 28 Jan 2006 New trial record.